Skip to main content

Table 1 Patients’ clinical characteristics and laboratory data

From: Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C

Features Cases (n = 680) Healthy (n = 164) P value
Male/Female, n 465/215 76/88  
Age (years) 54.9 ± 11.0 56.8 ± 14.8 0.02
IFN therapy N (%) 291 (42.8%) 0 (0.00%)  
Habitual alcohol intake N (%) 275 (40.4%)   
Body mass index 23.6 ± 3.1 24.0 ± 3.1 0.114
Platelet count (×109/l) 166.7 ± 74.8 228.3 ± 45.1 <0.001
AST (15–46 IU/l) 49.2 ± 39.9 26.4 ± 10.2 <0.001
ALT (0–40 IU/l) 37.7 ± 43.8 23.7 ± 15.1 0.011
GGT (12–73 IU/l) 63.7 ± 105.3 27.2 ± 27.7 <0.001
AFP (0–6.2 IU/l) 7.46 ± 33.9   
HCV genotype N (%)
 1b 126 (18.5%)   
 2a 94 (13.8%)   
 1b/2a 2 (0.3%)   
 Unknown 459 (67.4%)   
Fibrosis markers
APRI 1.06 ± 2.72 0.30 ± 0.13 <0.001
FIB4 4.84 ± 12.05 1.33 ± 0.55 <0.001
AST/ALT ratio 2.62 ± 2.80 1.45 ± 1.43 <0.001
GPR 0.58 ± 1.21 0.12 ± 0.12 <0.001
M2BPGi 1.57 ± 2.28 0.38 ± 0.23 <0.001
Fibrosis stage (0 ~ 1/2 ~ 3/4) 437/175/68 155/9/0